Catestatin and Hypertension in Pregnancy

Pre-Eclampsia Clinical Trial

Official title:

Relationship Between Catestatin and Pregnant Hypertensive Disorders

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03200743
• Other study ID #: 20170513
• Status: Recruiting
• Phase: N/A
• First received: June 19, 2017
• Last updated: June 26, 2017
• Start date: May 14, 2017
• Est. completion date: December 2017

Study information

• Verified date: June 2017
• Source: Peking University Third Hospital
• Contact: Yuchen Pan, MD
• Phone: +8618810533382
• Email: panyuchen[@]bjmu.edu.cn
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Catestatin is a kind of protein involved with cardiovascular disease. Accumulated evidence shows that Catestatin may be a predictor of primary hypertension, but whether it plays the same role in pregnant hypertensive disorders needs to be determined. By measuring the plasma level of Catestatin, main biochemical marks and UCG in healthy pregnancy and pregnancy with hypertension, the research may contribute to this problem.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 400
• Est. completion date: December 2017
• Est. primary completion date: December 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Healthy pregnancy women

• Pregnancy women with hypertension

1. Despite the pregnant gestational age , systolic blood pressure =140 mm Hg OR a diastolic blood pressure of =90 mm Hg measured three times more than 24 hours apart

2. Pregnant gestational age > 20 weeks, systolic blood pressure =140 mm Hg OR a diastolic blood pressure of =90 mm Hg measured twice more than 4 hours apart

Exclusion Criteria:

• Lack of blood sample at the specified enrollment period

• Women who refuse the study

• Other illness which needs medications interfering with blood pressure (eg: Asthma requiring systemic steroids)

• Known coronary artery disease or heart failure

• Serious medical illness (eg: renal insufficiency, congestive heart disease, chronic respiratory insufficiency, uncontrolled infection).

• multiple endocrine neoplasia or Cushing's syndrome or mixed tumours or pheochromocytoma or medullary thyroid carcinoma.

• previous history of malignant tumour, with the exception of carcinoma in situ of the uterine cervix or non-melanoma skin cancer

• renal insufficiency

Related Conditions & MeSH terms

• Eclampsia
• Hypertension
• Hypertension in Pregnancy
• Hypertension, Pregnancy-Induced
• Pre-Eclampsia

Locations

Country	Name	City	State
China	Peking University Third Hospital	Beijin	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Yuchen Pan

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	plasma level of Catestatin	plasma level of Catestatin with the unit "mmol/l"	once at the specified enrollment period
Secondary	blood pressure	systolic and diastolic blood pressure with the unit "mmHg"	the specified enrollment period,42 days and 2 months after the pregnancy